Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross ...
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into ...
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or ...
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) ...
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026. LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ( ...
With a new year underway, GRI is increasing momentum to deliver sustainability standards that strengthen the quality and usability of reporting, helping ...
The ruling confirms that alloys are classified by the metal predominating by weight. Since copper predominated, the brass ...
NSI N.V. ( NIUWF) Q4 2025 Earnings Call January 28, 2026 4:00 AM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results